Outcreating Smarter R&D Outcomes for a Global Life Sciences Leader through AI-driven Predictive AI

About the Client

The client is a global leader in pharmaceuticals, medical devices, and consumer health, with a large and complex clinical development portfolio spanning multiple therapeutic areas and geographies. With hundreds of concurrent studies and increasing pressure to accelerate molecule-to-market timelines, The client sought to modernize clinical trial planning, monitoring, and risk assessment across its R&D portfolio.

Market Trends

AI is rapidly transforming clinical trials by enhancing speed, predictability, and decision quality across the entire trial lifecycle. Research indicates that AI-driven trial design and execution can accelerate timelines reduce operational costs significantly. Advanced natural language processing (NLP) algorithms further amplify these gains by scanning electronic health records (EHRs), unstructured clinical notes, and laboratory data to identify eligible participants with unprecedented speed, accuracy, and scale—significantly improving recruitment efficiency and trial outcomes. Thus, there is a significant shift underway with life sciences and healthcare organizations leveraging AI for improved operational efficiency.

Challenges

The client’s clinical operations teams faced several structural and operational challenges that limited speed, consistency, and predictability:

• Manually intensive and repetitive clinical trial project planning and monitoring resulted in delayed insights and high operational overhead.
• Lack of standardized benchmarking practices to support objective, data-driven decision-making.
• Inability to quickly assess the probability of success for ongoing and newly proposed studies.
• Inconsistent planning approaches across new studies, leading to variability in timelines, costs, and resource utilization.
• Limited visibility into site-level performance, enrolment risks, and milestone slippages, increasing the likelihood of late-stage failures.

LTM’s Solution

LTM designed and implemented a one-stop, AI-driven clinical trials intelligence platform to future-proof the clients clinical development operations and enable proactive, risk-aware decision-making.

Key capabilities included:

• AI-led clinical trial risk assessment to proactively identify and mitigate risks impacting time-to-market.
• Unified AI platform for R&D portfolio planning, generating actionable insights across ongoing and planned studies.
• Real-time clinical trial risk scoring to de-risk timelines, costs, and operational dependencies.
• Visual project synopsis dashboards with continuous monitoring of critical clinical KPIs translates analytics into clear, actionable insights.
• Project analyzer for milestone-wise study progress tracking and variance analysis.
• Monte Carlo simulation engine to model and simulate thousands of trial scenarios, forecasting:
  • Timelines
  • Costs and budgets
  • Risk exposure under different study design and operational assumptions
• Standardized benchmarking using industry-recognized data sources such as ClinicalTrials.gov and WCG KMR benchmarks.
• NLP-based ad-hoc querying, enabling users to quickly identify projects at risk using natural language.
• Deep site-level intelligence, including enrollment trends, country and site performance, and timeline risk indicators.
• AI-driven resource allocation strategies to optimize staffing and ensure timely availability of critical resources across portfolio studies.

Tech Stack

Project Analyzer and Monte Carlo simulation engine
LTM’s Lumin and integrated with Planisware

Business Benefits

The AI-driven clinical trials management solution delivered measurable and transformative outcomes for the client including:

• 190 person-months saved annually by automating portfolio analysis, reporting, and monitoring activities.
• 80% reduction in late-stage trial failure risk, empowering study managers with earlier, more confident go/no-go decisions.
•  1,000+ trial scenarios simulated to proactively assess risk and optimize study design, timelines, and budgets.
•  Significantly improved consistency, predictability, and transparency across clinical trial planning and execution.
•  Accelerated, data-driven decision-making for R&D leadership and clinical operations, directly supporting faster time-to-market.

Conclusion

By embedding predictive AI at the core of clinical planning and monitoring, LTM enabled the organization to shift from reactive trial management to proactive, intelligence-led R&D execution. What was once a manually intensive and risk-prone process is now a unified, data-driven ecosystem powered by advanced analytics, Monte Carlo simulations, NLP insights, and industry benchmarks integrated with LTM’s Lumin and Planisware. The result was a marked improvement in predictability, transparency, and speed, saving 190 person-months annually, reducing late-stage trial failure risk by 80%, and empowering leadership with the confidence to make faster, evidence-based go/no-go decisions. With AI-driven foresight embedded across the portfolio, the client established a scalable foundation for more resilient, efficient, and accelerated molecule-to-market outcomes.

Outcreate predictable clinical outcomes with AI.
 

Connect with our life sciences experts today at https://www.ltm.com/contactus